ImmunityBio director granted 65,600 stock options

ImmunityBio director Michael D. Blaszyk received a grant of stock options covering 65,600 shares of common stock.

Rhea-AI Filing Summary

ImmunityBio director Michael D. Blaszyk received a grant of stock options covering 65,600 shares of common stock. The options have an exercise price of $7.25 per share and expire on June 9, 2036.

According to the award terms, subject to his continuing to be a Service Provider under ImmunityBio’s 2025 Equity Incentive Plan, 100% of the shares subject to the option will vest on the earlier of June 9, 2027 or the date immediately before the next annual stockholder meeting.

Insider Trade Summary

Grant/Award: 65,600 shares

Grant/Award 1 txn

Insider BLASZYK MICHAEL D

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	65,600	$0.00	$0.00

Holdings After Transaction: Stock Option (right to buy) — 65,600 contracts (Direct)

Footnotes (1)

1. F1. Subject to the reporting person's continuing to be a Service Provider (as defined in the Issuer's 2025 Equity Incentive Plan) through such applicable vesting date, one hundred percent (100%) of the shares subject to the award will vest on the earlier to occur of June 9, 2027 or the date immediately preceding the next annual meeting of stockholders.

Key Figures

Options granted: 65,600 options Exercise price: $7.25 per share Post-grant derivative holdings: 65,600 options +3 more

6 metrics

Options granted 65,600 options Stock Option (right to buy) grant to director

Exercise price $7.25 per share Strike price for the stock options

Post-grant derivative holdings 65,600 options Total derivative securities following the transaction

Vesting date June 9, 2027 or pre-annual meeting Cliff vesting date, subject to continued service

Option expiration June 9, 2036 Expiration date of the stock option award

Vesting percentage 100% of granted options All shares vest at the single vesting date

Key Terms

Stock Option (right to buy), 2025 Equity Incentive Plan, Service Provider, vesting

4 terms

Stock Option (right to buy) financial

"security_title: Stock Option (right to buy)"

2025 Equity Incentive Plan financial

"as defined in the Issuer's 2025 Equity Incentive Plan"

Service Provider financial

"Subject to the reporting person's continuing to be a Service Provider"

vesting financial

"100% of the shares subject to the award will vest"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did ImmunityBio (IBRX) report for Michael D. Blaszyk?

ImmunityBio reported that director Michael D. Blaszyk received a grant of stock options for 65,600 shares of common stock. These options are part of his compensation and give him the right to buy shares at a fixed price in the future.

How many ImmunityBio (IBRX) stock options were granted and at what price?

Michael D. Blaszyk was granted stock options on 65,600 shares of ImmunityBio common stock, with an exercise price of $7.25 per share. This price is what he would pay per share if he chooses to exercise the options later.

When do Michael D. Blaszyk’s ImmunityBio (IBRX) options vest?

All 65,600 options vest in a single tranche on the earlier of June 9, 2027 or the date immediately before ImmunityBio’s next annual stockholder meeting. Vesting requires that he continue as a Service Provider under the 2025 Equity Incentive Plan.

What is the expiration date of the ImmunityBio (IBRX) options granted to Michael D. Blaszyk?

The stock options granted to Michael D. Blaszyk expire on June 9, 2036. After that date, any unexercised options become worthless, so the potential benefit must be realized before the expiration if the share price exceeds the $7.25 exercise price.

Is the ImmunityBio (IBRX) Form 4 transaction a market purchase or a compensation grant?

The Form 4 transaction reflects a compensation-related grant of stock options, not a market purchase. The options were awarded with a $7.25 exercise price and vesting conditions tied to continued service, under ImmunityBio’s 2025 Equity Incentive Plan.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/10/2026 - 08:11 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

BLASZYK MICHAEL D

(Last) (First) (Middle)

C/O IMMUNITYBIO, INC.

3530 JOHN HOPKINS COURT

(Street)

SAN DIEGO CALIFORNIA 92121

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
ImmunityBio, Inc. [ IBRX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/09/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$7.25	06/09/2026		A		65,600		(1)	06/09/2036	Common Stock	65,600	$0	65,600	D

Explanation of Responses:

1. Subject to the reporting person's continuing to be a Service Provider (as defined in the Issuer's 2025 Equity Incentive Plan) through such applicable vesting date, one hundred percent (100%) of the shares subject to the award will vest on the earlier to occur of June 9, 2027 or the date immediately preceding the next annual meeting of stockholders.

Remarks:

Exhibit 24 - Power of Attorney

	/a/ David C. Sachs, as Attorney-in-Fact	06/10/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)